Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) just unveiled an update.
Zai Lab Limited announced the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the U.S. Securities and Exchange Commission. This regulatory filing is significant for stakeholders as it provides detailed insights into the company’s financial performance and operational status, which can impact its market positioning and investor confidence.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, with operations in Shanghai, China, and Cambridge, USA. The company focuses on developing and commercializing innovative therapies, primarily targeting oncology, autoimmune, and infectious diseases.
Average Trading Volume: 15,053,266
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.34B
Find detailed analytics on 9688 stock on TipRanks’ Stock Analysis page.